Biorbyt
![]() |
||
Products for advancing your discoveries From antibodies to proteins, biochemicals to ELISA kits, Biorbyt's high quality research products are available for you to enable world class research and contribution to a deeper understanding of life sciences.
A comprehensive catalog of life science research products covering the areas of Neuroscience, Signal transduction, Cell Biology, Cancer Metabolism, Cardiovascular and others
Product range :
Choose from over 100,000 primary antibodies and over 2,000 secondary antibodies. Monoclonals and polyclonals tested in a number of applications - WB, ELISA, IHC, FACS and many more.
Choose from over 7,000 proteins and over 400 active proteins. All of our proteins have been validated for use in ELISAs, WB and IHC-P
We have over 10,000 biochemicals for use in your research.
We have over 2,000 ELISA kits covering many research areas . Each kit comes with a fully detailed protocol and examples of expected results.
Website : https://www.biorbyt.com/
|
![SARS-CoV-2 - Tocilizumab - Therapeutic Candidates](https://www.clinisciences.com/it/upload/thumbs/therapeutic-covid-19-qycdbq-59f289.jpg)
SARS-CoV-2 - Tocilizumab - Therapeutic Candidates
Tocilizumab is a humanized monoclonal antibody that blocks the action of interleukin-6 (IL-6) receptors. The IL-6 receptor has two forms: the membrane form mIL6R and the soluble form sIL-6R. Tocilizumab can bind specifically to sIL-6R and mIL-6R and inhibit the transduction signal. It is commonly used in rheumatoid arthritis as it is immunosuppressive.
Since the beginning of the COVID-19 pandemic, it has been shown that in patients severely affected by COVID-19 caused by the SARS-CoV-2 virus, there was a "cytokine storm" that would be a major cause of mortality as the inflammatory overreaction would destroy tissues.
IL-6 is thought to be one of the mediators of the inflammation that follows the immune response against SARS-CoV-2 in the pulmonary alveoli and thus one of the cytokines responsible for this "cytokine storm" phenomenon. Tocilizumab may therefore be a good candidate for treatment of COVID-19.
Risultati della ricerca : 15 prodotto(i) trovato(i)
Limita la ricerca :
RUOCE / IVD
- Unconjugated 7
- human 2
- Primary antibody 7
- Biochemicals 6
- ELISA/ELISPOT 2
- ELISA 5
- FA 3
- FC 3
- ICC 2
- IF 2
- IP 2
- Monoclonal 4
- Recombinant 1
Cat#
Descrizione
Cond.
Priced
‹
›